Open AccessLedipasvir/sofosbuvir: the fixed dose combination in the new era of treatment for HCV
Author(s) -
Alessia Ciancio
Publication year - 2015
Publication title -
reviews in health care
Language(s) - English
Resource type - Journals
eISSN - 2038-6702
pISSN - 2038-6699
DOI - 10.7175/rhc.v6i3.1178
Subject(s) - ledipasvir , sofosbuvir , medicine , fixed dose combination , ribavirin , regimen , pill , hepatitis c virus , hepatitis c , simeprevir , chronic hepatitis , gastroenterology , virology , pharmacology , virus
Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications, other reasons for ineligibility and side-effects. The fixed dosed combination ledipasvir/sofosbuvir (LDV / SOF) is the first approved regimen that doesn’t require administration with interferon or ribavirin. LDV / SOF is also the first single-pill approved for the treatment of chronic HCV genotype 1 in both treatment-naïve and treatment-experienced patients. The results of the phase III studies demonstrate the combination has been very well tolerated and SVR rates consistently above 90%. Objective of this review is to present clinical evidence of efficacy and safety of the combination LDV / SOF in different subgroups of patients with HCV